Cholesterol efflux capacity: An introduction for clinicians

Gordon, 1977, High density lipoprotein as a protective factor against coronary artery disease. The Framingham Study, Am J Med, 62, 707, 10.1016/0002-9343(77)90874-9 Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Badimon, 1989, High density lipoprotein plasma fractions inhibit aortic fatty streak lesions in cholesterol-fed rabbits, Lab Invest, 60, 455 Rubin, 1991, Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI, Nature, 353, 265, 10.1038/353265a0 Tangirala, 1999, Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice, Circulation, 100, 1816, 10.1161/01.CIR.100.17.1816 Mortensen, 2015, The high-density lipoprotein–adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30 824 Europeans: the Copenhagen General Population Study, Eur Heart J, 36, 2446, 10.1093/eurheartj/ehv251 Taskinen, 2003, Diabetic dyslipidaemia: from basic research to clinical practice, Diabetologia, 46, 733, 10.1007/s00125-003-1111-y Jorgensen, 2014, Loss-of-function mutations in APOC3 and risk of ischemic vascular disease, N Engl J Med, 37, 32, 10.1056/NEJMoa1308027 Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2 Hasse, 2010, Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease, J Clin Endocrinol Metabol, 95, E500, 10.1210/jc.2010-0450 Hasse, 2012, LCAT, HDL cholesterol and ischemic cardiovascular disease: a mendelian randomization study of HDL cholesterol in 54,500 individuals, J Clin Endocrinol Metabol, 97, E248, 10.1210/jc.2011-1846 Barter, 2007, Effects of torcetrapib in patients at high risk for coronary events, N Engl J Med, 357, 2110, 10.1056/NEJMoa0706628 Investigators TAH, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579 Schwartz, 2012, Effects of dalcetrapib in patients with a recent acute coronary syndrome, N Engl J Med, 367, 2089, 10.1056/NEJMoa1206797 Rosensen, 2012, Cholesterol efflux and atheroprotection, advancing the concept of reverse cholesterol transport, Circulation, 125, 1905, 10.1161/CIRCULATIONAHA.111.066589 Heinecke, 2012, A new era for quantifying HDL and cardiovascular risk?, Nature, 18, 1346 Zhang, 2003, Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo, Circulation, 108, 661, 10.1161/01.CIR.0000086981.09834.E0 Eriksson, 1999, Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I potential reverse cholesterol transport in humans, Circulation, 100, 594, 10.1161/01.CIR.100.6.594 Alam, 2001, Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice, J Biol Chem, 276, 15641, 10.1074/jbc.M010230200 de la Llera, 1994, A cell culture system for screening human serum for ability to promote cellular cholesterol efflux: relationships between serum components and efflux, esterification, and transfer, Arterioscler Thromb, 14, 1056, 10.1161/01.ATV.14.7.1056 Rothblat, 1982, Mechanism of cholesterol efflux from cells: effects of acceptor structure and concentration, J Biol Chem, 257, 4775, 10.1016/S0021-9258(18)34593-9 Phillips, 2014, Molecular mechanisms of cellular cholesterol efflux, J Biol Chem, 289, 24020, 10.1074/jbc.R114.583658 Rohatgi, 2015, High-Density lipoprotein function measurement in human studies: focus on cholesterol efflux capacity, Prog Cardiovasc Dis, 58, 32, 10.1016/j.pcad.2015.05.004 Adorni, 2007, The role of different pathways in the release of cholesterol from macrophages, J Lipid Res, 48, 2453, 10.1194/jlr.M700274-JLR200 Du, 2015, HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export, Circ Res, 116, 1133, 10.1161/CIRCRESAHA.116.305485 Out, 2008, Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1, Circ Res, 102, 113, 10.1161/CIRCRESAHA.107.161711 Larrede, 2009, Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent, Arterioscler Thromb Vasc Biol, 29, 1930, 10.1161/ATVBAHA.109.194548 Remaley, 1997, Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux, Arterioscler Thromb Vasc Biol, 17, 1813, 10.1161/01.ATV.17.9.1813 van Dam, 2002, Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study, Lancet, 359, 37, 10.1016/S0140-6736(02)07277-X de la Llera-Moya, 2010, The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages, Arterioscler Thromb Vasc Biol, 30, 796, 10.1161/ATVBAHA.109.199158 Khera, 2011, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis, N Engl J Med, 364, 127, 10.1056/NEJMoa1001689 Li, 2013, Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks, Arterioscler Thromb Vasc Biol, 33, 1696, 10.1161/ATVBAHA.113.301373 Rohatgi, 2014, HDL cholesterol efflux capacity and incident cardiovascular events, N Engl J Med, 371, 2383, 10.1056/NEJMoa1409065 Saleheen, 2015, Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-controlstudy, Lancet Diabetes Endocrinol, 3, 507, 10.1016/S2213-8587(15)00126-6 Dahabreh, 2011, Index event bias as an explanation for the paradoxes of recurrence risk research, JAMA, 305, 822, 10.1001/jama.2011.163 Mody, 2016, Beyond coronary calcification, family history, and C-reactive protein. Cholesterol efflux capacity and cardiovascular risk prediction, J Am Coll Cardiol, 67, 2480, 10.1016/j.jacc.2016.03.538 Kontush, 2006, Antiatherogenic small, dense HDL—guardian angel of the arterial wall?, Nat Clin Pract Cardiovasc Med, 3, 144, 10.1038/ncpcardio0500 Jeyarajah, 2006, Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy, Clin Lab Med, 26, 847, 10.1016/j.cll.2006.07.006 Caulfield, 2008, Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis, Clin Chem, 54, 1307, 10.1373/clinchem.2007.100586 Rached, 1851, Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A, Biochim Biophys Acta, 2015, 1254 Tan, 2011, Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus, J Clin Lipidol, 5, 467, 10.1016/j.jacl.2011.06.016 Cavallero, 1995, Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles, Arterioscler Thromb Vasc Biol, 15, 2130, 10.1161/01.ATV.15.12.2130 Syvanne, 1996, Cholesterol eflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein, Atherosclerosis, 127, 245, 10.1016/S0021-9150(96)05962-X Igau, 1997, In vivo glucosylated LpA-I subfraction. Evidence for structural and functional alterations, Arterioscler Thromb Vasc Biol, 17, 2830, 10.1161/01.ATV.17.11.2830 Rosensen, 2016, Dysfunctional HDL and atherosclerotic cardiovascular disease, Nat Rev Cardiol, 13, 48, 10.1038/nrcardio.2015.124 de Vries, 2008, Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification, 196, 733 Yassine, 2014, Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes, Metabolism, 63, 727, 10.1016/j.metabol.2014.03.001 Solomon, 2003, Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis, Circulation, 107, 1303, 10.1161/01.CIR.0000054612.26458.B2 Wolfe, 2003, Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis, J Rheumatol, 30, 36 Shoenfeld, 2005, Accelerated atherosclerosis in autoimmune rheumatic diseases, Circulation, 112, 3337, 10.1161/CIRCULATIONAHA.104.507996 Ronda, 2013, Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus, Ann Rheum Dis, 1 Hua, 2009, Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease, Scand J Rheumatol, 38, 184, 10.1080/03009740802541470 Juarez-Rojas, 2008, High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus, Lupus, 17, 981, 10.1177/0961203308093072 Fournier, 1997, HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum, Arterioscler Thromb Vasc Biol, 17, 2685, 10.1161/01.ATV.17.11.2685 Agarwala, 2015, High-density lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease, Arterioscler Thromb Vasc Biol, 35, 1, 10.1161/ATVBAHA.115.305504 Soutar, 2006, Mechanisms of disease: genetic causes of familial hypercholesterolemia, Nat Clin Pract Cardiovasc Med, 4, 214, 10.1038/ncpcardio0836 Brown, 1986, A receptor-mediated pathway for cholesterol homeostasis, Science, 232, 34, 10.1126/science.3513311 Bellanger, 2011, Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia, Arterioscler Thromb Vasc Biol, 31, 1675, 10.1161/ATVBAHA.111.227181 Mehta, 2010, Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database, Eur Heart J, 31, 1000, 10.1093/eurheartj/ehp567 Gelfand, 2006, Risk of myocardial infarction in patients with psoriasis, JAMA, 296, 1735, 10.1001/jama.296.14.1735 Salahuddin, 2015, Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis, Eur Heart J, 36, 2662, 10.1093/eurheartj/ehv339 Brites, 2004, Enhanced cholesterol efflux promotion in well-trained soccer players, Metabolism, 53, 1262, 10.1016/j.metabol.2004.05.002 Koba, 2016, Beneficial effects of exercise-based cardiac rehabilitation on high-density lipoprotein-mediated cholesterol efflux capacity in patients with acute coronary syndrome, J Atheroscler Thromb, 23, 1, 10.5551/jat.34454 Sola, 1993, Dietary monounsaturated fatty acids enhance cholesterol efflux from human fibroblasts. Relation to fluidity, phospholipid fatty acid composition, overall composition and size of HDL3, Arterioscler Thromb Vasc Biol, 13, 958, 10.1161/01.ATV.13.7.958 Montoya, 2002, Fatty acid saturation of the diet and plasma lipid concentrations, lipoprotein particle concentrations, and cholesterol efflux capacity, Am J Clin Nutr, 75, 484, 10.1093/ajcn/75.3.484 Hernaz, 2014, Olive oil polyphenols enhance high-density lipoprotein function in humans. A randomized controlled trial, Arterioscler Thromb Vasc Biol, 34, 2115, 10.1161/ATVBAHA.114.303374 Osto, 2015, Rapid and body weight–independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass role of glucagon-like peptide-1, Circulation, 131, 871, 10.1161/CIRCULATIONAHA.114.011791 Bornfeldt, 2011, Insulin resistance, hyperglycemia, and atherosclerosis, Cell Metab, 14, 575, 10.1016/j.cmet.2011.07.015 Zimetti, 2006, Measurement of cholesterol bidirectional flux between cells and lipoproteins, J Lipid Res, 47, 605, 10.1194/jlr.M500466-JLR200 Rhainds, 2015, Abstract 17232: comparison of methods for the measurement of cholesterol efflux capacity of plasma HDL with J774 mouse macrophages reveals superiority of the radioactive cholesterol method over the BODIPY-cholesterol-2 method, Circulation, 132, A17232, 10.1161/circ.132.suppl_3.17232 Cignarella, 2005, Pharmacological regulation of cholesterol efflux in human monocyte–derived macrophages in the absence of exogenous cholesterol acceptors, Atherosclerosis, 179, 229, 10.1016/j.atherosclerosis.2004.11.005 Joseph, 2002, Synthetic LXR ligand inhibits the development of atherosclerosis in mice, Proc Natl Acad Sci U S A, 99, 7604, 10.1073/pnas.112059299 Grefhorst, 2002, Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles, J Biol Chem, 277, 34182, 10.1074/jbc.M204887200 Chinetti, 2001, PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway, Nat Med, 7, 53, 10.1038/83348 Ozasa, 2011, Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPAR/LXR pathway: findings from in vitro and ex vivo studies, Atherosclerosis, 219, 141, 10.1016/j.atherosclerosis.2011.07.113 Franceschini, 2007, Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients, Atherosclerosis, 195, 385, 10.1016/j.atherosclerosis.2006.10.017 Khera, 2015, Potent peroxisome proliferator–activated receptor-αagonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome, Eur Heart J, 1-3 Ormseth, 2015, Effect of drug therapy on net cholesterol efflux capacity of HDL-enriched serum in rheumatoid arthritis [abstract], Arthritis Rheum, 67 Nicholls, 2015, Cholesterol efflux capacity and pre–beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib, J Am Coll Cardiol, 66, 2201, 10.1016/j.jacc.2015.09.013 Nicholls S. Evacetrapib does not reduce major adverse cardiovascular events. Joint ACC/JAMA Late-Breaking Clinical Trials. Presented at: American College of Cardiology Scientific Session; April 2–4, 2016; Chicago. Havingh, 2015, Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial, Lancet, 386, 452, 10.1016/S0140-6736(15)60158-1